Clinical Trial Update: Romiplostim N01 for Chemotherapy-induced Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in China is recruiting to evaluate Romiplostim N01 for chemotherapy-induced thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• Romiplostim N01 (romiplostim)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Chemotherapy-induced Thrombocytopenia, Romiplostim N01 | Phase 2 | Status: RECRUITING